drugset / Trial / NCT01199718
Study of CX-4945 in Patients With Relapsed or Refractory Multiple Myeloma
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This Phase 1 study of oral CX-4945 is designed to test the safety, tolerability, and highest safe dose level of this CK2 inhibitor in patients with relapsed or refractory multiple myeloma.
Timeline
- Start
- 2010-09
- Primary completion
- 2011-06
- Completion
- 2011-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Silmitasertib | Small molecule | — | Oral |